Biostem Technologies (BSEM) investor relations material

Company overview and business model

• Develops and commercializes placenta- and umbilical-cord-derived allografts for advanced wound care and surgical use; products span dry, cryopreserved, and shelf-stable formats.

• Proprietary processing platforms are BioRetain, CryoTek, and SteriTek; portfolio includes Vendaje, Neox, Clarix, and other tissue products.

• January 2026 BioTissue asset acquisition added Neox and Clarix, sales infrastructure, and GPO/IDN relationships; manufacturing transfer may begin as early as 12 months after acquisition.

• Strategy centers on expanding into hospitals and ASCs, broadening products, scaling direct and independent sales, and moving acquired manufacturing in-house to improve supply efficiency and margins over time.

Financial performance and metrics

• FY2025 revenue was $47.48m vs. $69.66m in FY2024; net loss was $6.58m vs. net income of $31.03m.

• H1 2026 revenue was $14.03m vs. $26.93m in H1 2025; net loss was $17.79m vs. net income of $3.92m.

• June 30, 2026 cash was $6.96m, current assets $20.78m, current liabilities $21.20m, and accumulated deficit $38.97m.

• H1 2026 physician-office revenue fell 93% YoY to $1.87m; hospital revenue was $12.08m following the BioTissue acquisition.

• Management expects losses and negative operating cash flow over the next 12 months; auditors cited substantial doubt about continuing as a going concern.

Use of proceeds and capital allocation

• No proceeds from selling-stockholder resales; cash exercise of all warrants could generate gross proceeds of ~$5.6m for working capital and general corporate purposes.

• A separate Roth Principal Investments equity facility permits discretionary sales of up to $40m over as long as 36 months, subject to pricing, share-count, and other conditions; net proceeds are intended for working capital and general corporate purposes.

• Up to $10m is owed to BioTissue after Catalyze received 510(k) clearance; the payment remained unpaid in the filing, and debt and equity financing were being pursued.